Reply to Is There a Real Difference Between the First Onset of Efficancy for Atypicla Antipsychotic Monotherapies in Acute Bipolar Mania?"

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Dr. Treuer and Mr. Basson make an important point of clarification regarding the onset of efficacy for atypical antipsychotics in patients with acute mania. Although the data from placebo-controlled trials indicate that there were significant mean reductions in measures of manic symptoms from placebo at day 2 in patients receiving ziprasidone, at day 3 in patients receiving risperidone (in 1 trial), and at day 4 in patients receiving aripiprazole, these data should not be construed to imply differences in onset of efficacy. They do indeed represent the timepoints at which improvement was first assessed following baseline evaluations prior to randomization in these trials.​

J Clin Psychiatry 2005;66(10):1334-1334 [letter]